CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
INV-102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05586152
NCT05586152Phase 2Completed

Phase 1/2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Multiple Ascending Dose (Part 1) and Optional Dose Expansion (Part 2) Study of INV-102 Ophthalmic Solution in Adult Subjects With Moderate Symptomatic Dry Eye Disease

Invirsa, Inc.·interventional·Posted Oct 19, 2022·Updated Apr 27, 2026

In Brief

A Phase 2 clinical trial evaluating INV-102 and Vehicle for Dry Eye Disease. Completed, enrolled 84 participants across 1 site.

Detailed Summary

Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the treatment of moderate symptomatic dry eye disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedOct 19, 2022
Enrollment StartAug 30, 2022
Primary CompletionMay 2, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.7 years ago

Interventions

INV-102drug

INV-102 Ophthalmic Solution

Vehicledrug

Vehicle Ophthalmic Solution